COVID-19 vaccines work—but immunocompromised individuals may not produce as strong an immune response. Evusheld became the first treatment to protect this group before exposure to the virus when it received emergency authorization from the FDA in December 2021. The antibody therapy—made by AstraZeneca and given by injection to people at high risk of developing serious disease if they get COVID-19—is a combination of two monoclonal antibodies that soak up virus proteins to prevent them from infecting healthy cells. There is a downside of antibody-based treatments like Evusheld, however: viruses can mutate to become resistant to them. The FDA has warned that the therapy might not be as effective with newer Omicron variants compared to previous strains of SARS-CoV-2.
- Column: The Tyre Nichols Videos Demand Solemnity, Not Sensationalism
- For People With Disabilities, Losing Abortion Access Can Be a Matter of Life or Death
- Inside the Clandestine Efforts to Smuggle Starlink Internet Into Iran
- How to Help the Victims and Community After the Monterey Park Shooting
- The Biggest Snubs and Surprises of the 2023 Oscar Nominations
- Talking Less Will Get You More
- Kamala Harris Subtly Emerges as Powerful White House Asset
- How Avatar: The Way of Water Became the 6th Movie in History to Make $2 Billion
- Is There Really No Safe Amount of Drinking?
- How Our Cells Strategize To Keep Us Alive